Stock · HSIC · Healthcare
United States · Mid Cap · listed since 1995 · Revenue 12 mo. $13.7B
Price as of 11/06/2026
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Original text from the data provider
Summary
43.4 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €514.2M (2025), it supports €5.7B. The remaining €3.1B of the market value assume it grows 6.1% a year for 10 years and not at all afterwards.
Required FCF growth per year
6.1%
no growth afterwards
Price to operating cash flow 14.1×, within its usual range.
Middle half of 20 quarters: 13.4× to 16.4×, median 14.7×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
7 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, FCF margin, Net debt, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 12.27% | 11.52% | Rank 55 |
| Return on capital (Greenblatt) | 35.13% | 32.55% | Rank 54 |
| EBIT margin | 5.75% | 18.31% | Rank 18 |
| FCF margin | 4.35% | 14.12% | Rank 17 |
| Gross margin | 29.14% | 60.99% | Rank 17 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 4.03% | 8.04% | Rank 26 |
| Earnings growth, 3 years per year | −5.75% | 5.44% | Rank 25 |
| Earnings growth, 5 years per year | 3.12% | 7.00% | Rank 38 |
| Sustainable growth (ROE × retained earnings) | 1.05% | 3.66% | Rank 15 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.80% | 2.90% | Rank 66 |
| FCF yield | 5.82% | 3.63% | Rank 79 |
| EV/saleslower is better | 1.01 | 4.03 | Rank 86 |
| EV/EBITlower is better | 17.64 | 21.73 | Rank 67 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 13.22% | 8.66% | Rank 55 |
| Share price, 6 months | 21.99% | 24.27% | Rank 46 |
| Share price, 3 months | 2.77% | 15.42% | Rank 19 |
| Distance from 52-week high | −5.29% | −7.35% | Rank 58 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 1.52% | 0.30% | Rank 41 |
| Change in share countlower is better | −4.74% | 0.00% | Rank 94 |
| Dividend streak in yearsdoes not count towards the rank | – | 10 | |
| Price reaction to results, market-adjusted | −4.82% | 0.05% | Rank 13 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 28.93% | 48.40% | Rank 19 |
| Net debt/EBITDAlower is better | 3.51 | 1.11 | Rank 12 |
| Debt to equitylower is better | 1.14 | 0.48 | Rank 16 |
| Volatility, 1 yearlower is better | 24.88% | 31.42% | Rank 89 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $M | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 11.6 | 7.1% | 545.3 | 162M | $1.2B |
| 2017 | 12.5 | 6.9% | 464.0 | 158M | $1.5B |
| 2018 | 13.2 | 5.3% | 594.1 | 154M | $1.9B |
| 2019 | 10.0 | 7.3% | 577.9 | 149M | $892.3M |
| 2020 | 10.1 | 5.6% | 550.0 | 143M | $581.2M |
| 2021 | 12.4 | 6.9% | 630.6 | 142M | $1.1B |
| 2022 | 12.6 | 7.4% | 506.0 | 138M | $1.4B |
| 2023 | 12.3 | 5.8% | 313.0 | 132M | $2.6B |
| 2024 | 12.7 | 5.8% | 661.0 | 128M | $2.7B |
| 2025 | 13.2 | 5.8% | 573.0 | 122M | $3.5B |
3 of 7 StockScorer Score rules met · How the score is built
Henry Schein Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Henry Schein Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Henry Schein Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 26.3 | 30.0 |
| P/B ratio | 3.2 | 4.8 |
| Return on equity (ROE) | 12.3% | 11.5% |
| Equity ratio | 28.9% | 48.4% |
| Debt-to-equity (D/E) | 1.14 | 0.48 |
| Dividend yield | – | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| HSIC | Henry Schein Incthis page | |
| SIG.AX | Sigma Healthcare Ltd | locked |
| M12.DE | M1 Kliniken AG | High6.4 |
| CAH | Cardinal Health Inc | Medium5.5 |
| COR | Cencora Inc. | locked |
| MCK | McKesson Corporation | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.